Related Experiment Video
Updated: Jun 24, 2025
Comparative Lesions Analysis Through a Targeted Sequencing Approach
Published on: November 5, 2019
In silico analysis of several frequent SLX4 mutations appearing in human cancers
Korey Bosart1, Ruben C Petreaca2,1, Renee A Bouley3
1James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, United States.
Abstract:
SLX4 is an interactor and activator of structure-specific exonuclease that helps resolve tangled recombination intermediates arising at stalled replication forks. It is one of the many factors that assist with homologous recombination, the major mechanism for restarting replication. SLX4 mutations have been reported in many cancers but a pan cancer map of all the mutations has not been undertaken. Here, using data from the Catalogue of Somatic Mutations in Cancers (COSMIC), we show that mutations occur in almost every cancer and many of them truncate the protein which should severely alter the function of the enzyme. We identified a frequent R1779W point mutation that occurs in the SLX4 domain required for heterodimerization with its partner, SLX1. In silico protein structure analysis of this mutation shows that it significantly alters the protein structure and is likely to destabilize the interaction with SLX1. Although this brief communication is limited to only in silico analysis, it identifies certain high frequency SLX4 mutations in human cancers that would warrant further in vivo studies. Additionally, these mutations may be potentially actionable for drug therapies.
Insights
SLX4 mutations are frequent in nearly all cancers, often truncating the protein and disrupting DNA repair. A specific mutation (R1779W) severely impacts SLX1 interaction, suggesting potential therapeutic targets.
Area of Science:
- Genetics
- Molecular Biology
- Cancer Research
Background:
- SLX4 protein is crucial for resolving DNA recombination intermediates during replication stress.
- It plays a vital role in homologous recombination, a key pathway for restarting stalled replication forks.
- Previous studies noted SLX4 mutations in various cancers, but a comprehensive analysis was lacking.
Purpose of the Study:
- To create a pan-cancer map of SLX4 mutations.
- To investigate the functional impact of identified high-frequency mutations.
- To explore potential therapeutic implications of SLX4 mutations in cancer.
Main Methods:
- Analysis of somatic mutation data from the Catalogue of Somatic Mutations in Cancers (COSMIC).
- Identification and characterization of frequent SLX4 mutations across diverse cancer types.
- In silico protein structure analysis of the R1779W mutation to assess its effect on SLX1 interaction.
Main Results:
- SLX4 mutations were found in almost every cancer type analyzed.
- Many identified mutations lead to protein truncation, likely impairing SLX4 function.
- A recurrent R1779W mutation was identified in the SLX1-binding domain, predicted to destabilize heterodimerization.
- In silico analysis indicated significant structural alterations due to the R1779W mutation.
Conclusions:
- SLX4 mutations are widespread across human cancers and frequently result in functional protein alterations.
- The R1779W mutation represents a significant disruption in SLX4-SLX1 interaction, warranting further investigation.
- These findings highlight SLX4 mutations as potential targets for novel cancer therapies.
